Method for identifying platinum cross-linked peptide fragment

Through cross-linking and enzyme digestion of platinum cross-linking agents and proteins, combined with pLink2 and MS2-autoassign-Pt software tools, the precise identification and site positioning of platinum cross-linked peptides was achieved, and the platinum in the existing technology was solved The difficulties in identification and site localization of crosslinked peptides have improved the analytical capabilities of protein structure and drug research.

CN118914563APending Publication Date: 2024-11-08SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411004038.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to accurately identify platinum crosslinked peptides and accurately locate their crosslinking sites, resulting in limited protein structure analysis and toxicity research on platinum drug resistance.

Method used

By crosslinking the platinum crosslinking agent with protein and digesting it with enzyme, mass spectral data of candidate platinum crosslinking peptides were obtained, and the pLink2 software and MS2-autoassign-Pt were used for screening and matching, and false positive data were removed in combination with isotope matching. Multiple types of fragment ion libraries were merged to screen out platinum crosslinked peptides and their crosslinking sites were located.

Benefits of technology

The precise identification of platinum crosslinked peptides and the precise localization of crosslinked sites have been achieved, and the support capabilities of protein structure analysis and toxicity research on platinum drug resistance are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914563A_ABST
    Figure CN118914563A_ABST
Patent Text Reader

Abstract

The invention discloses a method for identifying platinum cross-linked peptide fragments, which comprises the following steps of: performing mass spectrum identification on each candidate platinum cross-linked peptide fragment obtained by performing cross-linking and enzyme digestion on a platinum cross-linking agent and protein to obtain spectrogram data of each candidate platinum cross-linked peptide fragment; on the basis of the spectrogram data of each candidate platinum cross-linked peptide fragment, fragment ions which cannot be fractured by mass spectrum, fragment ions which can be fractured by mass spectrum, fragment ions which are fractured by alpha peptide fragment and beta peptide fragment, and fragment ions generated by fracture of side chains of platinum cross-linking agents are obtained, and then the platinum cross-linked peptide fragments are obtained through screening. The precise identification of the platinum cross-linked peptide fragment is realized; and based on fragment ions, accurate positioning of a crosslinking site of the platinum crosslinking peptide fragment is realized. By means of the identification method, more platinum cross-linked peptide fragments can be obtained through identification, meanwhile, the identification accuracy can be guaranteed, the cross-linking sites of the platinum cross-linked peptide fragments can be accurately located, protein structure analysis is achieved, and drug resistance and / or toxicity research of platinum drugs is guided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of bioanalysis, and in particular to a method for identifying platinum cross-linked peptide segments. Background Art

[0002] Chemical cross-linking combined with mass spectrometry technology is widely used in the structural study of proteins and the interpretation of protein-protein interactions. The complete workflow of the classic cross-linking mass spectrometry can be roughly divided into five steps: 1. cross-linking experiment, 2. enzyme cleavage experiment, 3. mass spectrometry experiment, 4. data analysis and 5. comprehensive application; among them, the development of cross-linking agents and the analysis of cross-linking data are the two most critical steps in chemical cross-linking combined with mass spectrometry technology.

[0003] Since the joint application of chemical cross-linking and mass spectrometry technology, the innovation and development of cross-linking agents and cross-linking mass spectrometry data analysis software have been the source of changes in the field. In the early days, the analysis of cross-linking data mainly relied on primary mass spectrometry identification. With the development of cross-linking agents, some identification software adapted to cross-linking agents gradually emerged, such as Blinks software adapted to PIR cross-linking agents, etc.; then the emergence of open search algorithms greatly supported the identification of non-breakable cross-linking agents; at the same time, the emergence of mass spectrometry breakable cross-linking agents also gave rise to the development of search engines that rely on characteristic peak ion identification.

[0004] Currently, pLink2 is a search engine that supports the identification of non-cleavable cross-linkers, and MetaMorpheus is a search engine that supports the identification of cleavable cross-linkers. These software are mature and robust at the forefront of development. Classic cross-linkers such as mass spectrometry non-cleavable cross-linker DSS and mass spectrometry cleavable cross-linker DSSO are stable and easy to search, but they have fewer targeted structures and sparse data density; there are also some non-specific cross-linkers such as photoreactive cross-linkers, but the nature of non-specific cross-linkers targeting all amino acids leads to more complex cross-linking products, more explosive database search needs, and the problem of eliminating false positive data also limits development.

[0005] Platinum drugs are a class of anti-tumor drugs based on DNA enzyme inhibitors. Studies have found that Pt(II) can be used as a protein cross-linking agent and has many unique properties and advantages. First, Pt(II) has a strong binding affinity for sulfur-containing, nitrogen-containing, and carboxyl- or hydroxyl-containing amino acid ligands. Therefore, Pt(II) can react with many different types of amino acids, such as methionine (Met), cysteine ​​(Cys), histidine (His), aspartic acid (Asp), glutamic acid (Glu), arginine (Arg), lysine (Lys), tyrosine (Tyr), serine (Ser) and threonine (Thr). This property can greatly improve the cross-linking data density and the information richness of structure identification. degree; secondly, Pt(II) carries two inherent positive charges. The higher charge state is not only helpful for enriching cross-linked peptides by non-experimental methods such as charge screening, but also its secondary mass spectrometry fragmentation pattern is more comprehensive, which greatly assists in the identification of cross-linking sites; at the same time, Pt(II) has a special mass spectrometry isotope peak distribution, which can be used as an identification feature, making it possible to visualize the identification of platinum-containing peptides, extract cross-linked peptides containing metal isotope peaks by software, and use isotope matching to assist in the exclusion of false positives; and Pt(II) and its analogs can not only cross-link DNA, but also proteins and RNA, and the length of their cross-linking arms is usually between 2A and 5A, which is helpful for providing high-resolution fine structures, drawing the dynamics of flexible regions, and describing interactions. Therefore, using Pt(II)-type small molecules as information metal cross-linking agents is not only helpful for the study of protein structure and interaction, but also can supplement the toxicity and drug resistance mechanism of anticancer drugs, providing data support and guidance for clinical research. Although the cross-linking ability of Pt(II) has been demonstrated by many studies, the fine structure and flexible regions of proteins captured by platinum-based cross-linking reagents have rarely been reported due to the lack of analysis software suitable for platinum-containing cross-linking data.

[0006] Since the bond energy of the metal coordination bond of platinum cross-linking reagents is between that of non-covalent bonds and peptide covalent bonds, various types of fragment ions, such as mass spectrometry-breakable and mass spectrometry-indestructible, will be generated in the tandem mass spectrometry. Based on this, search engines designed for indestructible cross-linkers, such as pLink2, cannot fully match the fragment examples generated by the breakage of Pt(II)-containing cross-linked peptides. At the same time, search engines designed for mass spectrometry-breakable cross-linkers, such as MaxLynx, rely on the fragment ion peaks generated by the breakage of cross-linkers with very low bond energies when searching for peptides. The bond energy of the metal coordination bond of platinum cross-linkers is only slightly lower than that of peptide covalent bonds. This also leads to the inability of search engines designed for mass spectrometry-breakable cross-linkers to identify the characteristic fragment ions of platinum cross-linked peptides, which in turn leads to the inability to accurately identify platinum cross-linked peptides and achieve precise positioning of cross-linking sites.

[0007] Therefore, there is an urgent need for a method that can accurately identify platinum cross-linked peptides and accurately locate the cross-linking sites of platinum cross-linked peptides, thereby achieving fine structural analysis of protein structure, elucidation of protein-protein interactions, and research on drug resistance and toxicity of platinum drugs. Summary of the invention

[0008] The purpose of the present invention is to overcome the above-mentioned deficiencies of the prior art and provide a method for identifying platinum cross-linked peptides.

[0009] The first object of the present invention is to provide a method for identifying platinum cross-linked peptides.

[0010] The second object of the present invention is to provide application of the above identification method in identifying platinum cross-linked peptides.

[0011] The third object of the present invention is to provide the application of the above identification method in locating the cross-linking site of the platinum cross-linked peptide segment.

[0012] The fourth object of the present invention is to provide application of the above identification method in analyzing protein structure.

[0013] The fifth object of the present invention is to provide the application of the above identification method in guiding the research on drug resistance and / or toxicity of platinum drugs.

[0014] In order to achieve the above object, the present invention is implemented by the following scheme:

[0015] A method for identifying platinum cross-linked peptides comprises the following steps:

[0016] S1. cross-linking the platinum cross-linking agent and the protein and performing enzyme cleavage to obtain candidate platinum cross-linked proteins and performing mass spectrometry detection to obtain spectrum data of candidate platinum cross-linked peptides;

[0017] S2. Input the spectrum data of each candidate platinum cross-linked peptide obtained in step S1 into pLink2 software for identification, obtain the α peptide and β peptide of each candidate platinum cross-linked peptide, and match the fragment ions y and b of each candidate platinum cross-linked peptide, as well as the fragment ions Y and B of the platinum cross-linked peptide that cannot be broken by mass spectrum;

[0018] S3. The α peptide segment and β peptide segment of each candidate platinum cross-linked peptide segment obtained in step S2 are respectively input into MS2-autoassign-Pt, and each screened platinum cross-linked peptide segment is obtained after removing false positive data by isotope matching, and the mass spectrometry fragment ions Y' ions and B' ions of the α peptide segment and β peptide segment of each screened platinum cross-linked peptide segment, as well as the fragment ion 1 of the side chain breakage of the platinum cross-linker shown in step S1 are identified;

[0019] The false positive data are: candidate platinum cross-linked peptides with less than 2 fragment ions containing 3 platinum isotope peaks in the isotope matching results;

[0020] S4. The α peptide segment and the β peptide segment of each screened platinum cross-linked peptide segment obtained in step S3 are simultaneously input into MS2-autoassign-Pt for identification, and the fragment ions Y" and B" ions of the α peptide segment and the β peptide segment of each screened cross-linked peptide segment are obtained, as well as the fragment ion 2 of the side chain of the platinum cross-linking agent shown in step S1;

[0021] S5. Combine the y ion, b ion, Y ion, B ion obtained in step S2, the Y' ion, B' ion, fragment ion 1 obtained in step S3, the Y" ion, B" ion and fragment ion 2 obtained in step S4 to obtain a fragment ion library of each screened platinum cross-linked peptide segment;

[0022] S6. removing peptides that do not meet the conditions from the screened platinum cross-linked peptides obtained in step S3 to obtain platinum cross-linked peptides;

[0023] The condition is that each of the screened platinum cross-linked peptide segments contains at least 4 fragment ions in the fragment ion library obtained in step S5.

[0024] Preferably, the platinum cross-linking agent in step S1 is a cis-platinum cross-linking agent and / or a trans-platinum cross-linking agent;

[0025] The chemical formula of the cis-platinum cross-linking agent is shown in Formula I, and the chemical formula of the cis-platinum cross-linking agent is shown in Formula II;

[0026]

[0027]

[0028] Wherein R1 and R2 are inert groups, and X1 and X2 are active groups.

[0029] Preferably, the inert groups are amino ligands, alkyl ligands, sulfur-containing ligands, cyclic amine ligands, aromatic ligands and / or heterocyclic ligands; and the active groups are halide ions, water groups, organic acid radicals, hydroxide radicals and / or alkoxy acids.

[0030] More preferably, the platinum cross-linking agent is reverse platinum.

[0031] Preferably, the cross-linking of the platinum cross-linking agent and the protein in step S1 is specifically as follows:

[0032] The protein is cross-linked with a platinum cross-linking agent at 25°C to 37°C, and then the reaction is quenched with a quencher.

[0033] More preferably, the cross-linking reaction is carried out at 37°C.

[0034] More preferably, the cross-linking reaction time is 10 to 60 minutes.

[0035] More preferably, the cross-linking reaction time is 60 min.

[0036] More preferably, the quencher is histidine.

[0037] Preferably, the enzymatic cleavage in step S1 specifically comprises: using urea to denature the platinum cross-linked protein obtained by cross-linking the platinum cross-linking agent and the protein, and then using trypsin to perform enzymatic cleavage.

[0038] Preferably, the parameters of the pLink2 software in step S2 are set as follows:

[0039] Crosslinker: Pt1N2H4, Pt1N1H1, Pt1H -2 ;

[0040] flow type: conventional crosslinking (HCD);

[0041] Precursor ion mass tolerance: ±1~±20ppm;

[0042] fragment tolerance: ±1~±20ppm;

[0043] Enzymatic specificity: trypsin KR_C; semi-specific;

[0044] variable modification:oxidation(M);

[0045] filter tolerance: ±1~±20ppm;

[0046] The false discovery rate (FDR): 100%.

[0047] Preferably, the parameters of MS2-autoassign-Pt shown in step S3 are set to: formula of labeling: Pt1N2H4, Pt1N1H1, Pt1H -2 ;Tolerance in ppm: 1~50; intensity cutoff%: 1%~10%.

[0048] Preferably, the parameters of MS2-autoassign-Pt shown in step S4 are set to: formula of labeling: Pt1N2H4, Pt1N1H1, Pt1H -2 ;Tolerance in ppm: 1~50; intensity cutoff%: 1%~10%.

[0049] Preferably, the method further comprises step S7: locating the cross-linking sites of the platinum cross-linked peptides obtained in step S6 based on the fragment ion library of each screened platinum cross-linked peptide obtained in step S5.

[0050] The identification method of the present invention fully considers various types of fragment ions generated by platinum cross-linked peptides during the mass spectrometry process, including fragment ions that cannot be broken by mass spectrometry, fragment ions that can be broken by mass spectrometry, fragment ions in which both α peptides and β peptides are broken, and fragment ions generated by the breakage of the side chain of the platinum cross-linker. The candidate platinum cross-linked peptides obtained by the cross-linking mass spectrometry are screened based on the above-mentioned fragment ions, and then the platinum cross-linked peptides are obtained, thereby achieving accurate identification of the platinum cross-linked peptides; at the same time, the cross-linking sites of the platinum cross-linked peptides are accurately located based on the fragment ions, thereby determining the cross-linking sites of the platinum cross-linking sites.

[0051] The present invention also seeks to protect the use of any of the above-mentioned identification methods in identifying platinum cross-linked peptides.

[0052] The present invention also seeks to protect the use of any of the above-mentioned identification methods in locating the cross-linking sites of platinum cross-linked peptide segments.

[0053] The present invention also seeks to protect the application of any of the above-mentioned identification methods in analyzing protein structure.

[0054] The present invention also seeks to protect the use of any of the above-mentioned identification methods in guiding the study of drug resistance and / or toxicity of platinum drugs.

[0055] Compared with the prior art, the present invention has the following beneficial effects:

[0056] The present invention provides a method for identifying platinum cross-linked peptides, by cross-linking platinum cross-linking agents and proteins and performing mass spectrometry identification on each candidate platinum cross-linked peptide obtained by enzyme digestion, obtaining spectral data of each candidate platinum cross-linked peptide, and obtaining mass spectrum-indestructible fragment ions, mass spectrum-destructible fragment ions, fragment ions of both α-peptide and β-peptide fragments, and fragment ions generated by the cleavage of the side chain of the platinum cross-linking agent based on the spectral data of each candidate platinum cross-linked peptide, screening each candidate platinum cross-linked peptide to obtain platinum cross-linked peptides, and achieving accurate identification of platinum cross-linked peptides; at the same time, accurate positioning of the cross-linking sites of platinum cross-linked peptides based on the fragment ions. The identification method shown in the present invention can not only identify a larger number of platinum cross-linked peptides, but also ensure accurate identification of platinum cross-linked peptides, and can also accurately locate the cross-linking sites of platinum cross-linked peptides, thereby achieving protein structure analysis and guiding the drug resistance and / or toxicity research of platinum drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 This is a flow chart for identifying the platinum cross-linked peptides shown in Example 1;

[0058] Figure 2 is the secondary mass spectrum of the platinum cross-linked peptide segment 1 in Example 2; A is the secondary mass spectrum of the platinum cross-linked peptide segment 1 Figure 1 , B is the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 2 , C is the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 3 ;

[0059] Figure 3 is the secondary mass spectrum of the platinum cross-linked peptide segment 2 in Example 3; A is the secondary mass spectrum of the platinum cross-linked peptide segment 2 Figure 1 , B is the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 2 , C is the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 3 ;

[0060] Figure 4 is the secondary mass spectrometry spectrum of the platinum cross-linked peptide segment 3 in Example 2; A is the secondary mass spectrometry spectrum of the platinum cross-linked peptide segment 3 Figure 1 , B is the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 2 , C is the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 3 . DETAILED DESCRIPTION

[0061] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0062] Example 1 A method for identifying platinum cross-linked peptides

[0063] 1. Experimental Methods

[0064] 1. A method for identifying platinum cross-linked peptides

[0065] The identification flow chart of platinum cross-linked peptides is as follows Figure 1 As shown, the details are as follows:

[0066] (1) Protein GPb (P00489) and platinum crosslinker Transplatin (transplatin, expressed as Pt1N2H4) were mixed at a molar ratio of 1:50, and the crosslinking reaction was carried out at 37°C for 60 minutes. Then, the quencher Histidine was added at a molar ratio of 1:50 to the platinum crosslinker and the quencher for 30 minutes to obtain a platinum crosslinked protein;

[0067] The platinum cross-linked protein was mixed with 16M urea at a volume ratio of 1:1 and denatured for 10 minutes. The denatured platinum cross-linked protein was then diluted with an aqueous ammonium bicarbonate solution until the denatured platinum cross-linked protein contained 1.6M urea, thereby obtaining a diluted platinum cross-linked protein solution.

[0068] 0.1 μg of trypsin was added to 2 μg of diluted platinum cross-linked protein solution and digested for 12 hours, then desalted using a C18 column and diluted to 0.1 μg / μL of protein in the platinum cross-linked protein solution to obtain candidate platinum cross-linked peptides, which were then detected by mass spectrometry to obtain spectral data for each candidate platinum cross-linked peptide.

[0069] (2) inputting the spectrum data of each candidate platinum cross-linked peptide obtained in step (1) into pLink2 software for identification, obtaining the α peptide and β peptide of each candidate platinum cross-linked peptide, and matching the fragment ions y and b of each candidate platinum cross-linked peptide, as well as the fragment ions Y and B of the platinum cross-linked peptide that cannot be broken by mass spectrum;

[0070] The parameters of the pLink2 software are set as follows: Crosslinker: Pt1N2H4, Pt1N1H1, Pt1H -2 ;

[0071] flow type: conventional crosslinking (HCD);

[0072] Precursor ion mass tolerance: ±15ppm;

[0073] fragment tolerance:±15ppm;

[0074] Enzymatic specificity: trypsin KR_C; semi-specific;

[0075] variable modification:oxidation(M);

[0076] Filter tolerance: ±10ppm;

[0077] The false discovery rate (FDR): 100%.

[0078] (3) the α peptide segment and the β peptide segment of each candidate platinum cross-linked peptide segment obtained in step (2) are respectively input into MS2-autoassign-Pt, and the false positive data are removed by isotope matching to obtain each screened platinum cross-linked peptide segment, and the mass spectrum fragment ions Y' ions and B' ions of the α peptide segment and the β peptide segment of each screened platinum cross-linked peptide segment are identified, as well as the fragment ion 1 of the side chain cleavage of the platinum cross-linker shown in step S1;

[0079] The false positive data are: candidate platinum cross-linked peptides with less than 2 fragment ions containing 3 platinum isotope peaks in the isotope matching results;

[0080] MS2-autoassign-Pt is derived from the Github database (github.com / HARUDAY404 / MS2-autoassign-Pt). The parameters of MS2-autoassign-Pt are set as follows: formula of labeling: Pt1N2H4, Pt1N1H1, Pt1H -2 ;Tolerance in ppm: 50; Intensity cutoff%: 5%.

[0081] (4) The α peptide segment and the β peptide segment of each post-screening platinum cross-linked peptide segment obtained in step (3) are simultaneously input into MS2-autoassign-Pt for identification, and the fragment ions Y" and B" ions of the α peptide segment and the β peptide segment of each post-screening cross-linked peptide segment are obtained, as well as the fragment ion 2 of the side chain cleavage of the platinum cross-linking agent Transplatin (reverse platinum) shown in step 1 are obtained;

[0082] The parameter settings of MS2-autoassign-Pt are exactly the same as those in step (3).

[0083] (5) Combining the y ion, b ion, Y ion, B ion obtained in step (2), the Y' ion, B' ion, fragment ion 1 obtained in step (3), the Y" ion, B" ion and fragment ion 2 obtained in step (4) to obtain a fragment ion library of each screened platinum cross-linked peptide segment.

[0084] (6) removing peptides that do not meet the conditions from the screened platinum cross-linked peptides obtained in step (3) to obtain platinum cross-linked peptides;

[0085] The condition is that the screened platinum cross-linked peptides contain at least two fragment ions in the fragment ion library of each screened platinum cross-linked peptide obtained in step (5).

[0086] 2. Identification of platinum cross-linked peptides using pLink2

[0087] (1) Protein GPb (P00489) and platinum crosslinker Transplatin (transplatin, expressed as Pt1N2H4) were mixed at a molar ratio of 1:50, and the crosslinking reaction was carried out at 37°C for 60 minutes. Then, the quencher Histidine was added at a molar ratio of 1:50 to the platinum crosslinker and the quencher for 30 minutes to obtain a platinum crosslinked protein;

[0088] The platinum cross-linked protein was mixed with 16M urea at a volume ratio of 1:1 and denatured for 10 minutes. The denatured platinum cross-linked protein was then diluted with an aqueous ammonium bicarbonate solution until the denatured platinum cross-linked protein contained 1.6M urea, thereby obtaining a diluted platinum cross-linked protein solution.

[0089] 0.1 μg of trypsin was added to 2 μg of diluted platinum cross-linked protein solution and digested for 12 hours, then desalted using a C18 column and diluted to 0.1 μg / μL of protein in the platinum cross-linked protein solution to obtain candidate platinum cross-linked peptides, which were then detected by mass spectrometry to obtain spectral data for each candidate platinum cross-linked peptide.

[0090] Input the spectrum data of each candidate platinum cross-linked peptide obtained in step (1) into the pLink2 software for identification, obtain the α peptide and β peptide of each candidate platinum cross-linked peptide, and match the fragment ions y and b of each candidate platinum cross-linked peptide, as well as the fragment ions Y and B of the platinum cross-linked peptide that cannot be broken by mass spectrum, and obtain the platinum cross-linked peptide 1 output by the pLink2 software;

[0091] The parameters of the pLink2 software are set as follows: Crosslinker: Pt1N2H4, Pt1N1H1, Pt1H -2 ;

[0092] flow type: conventional crosslinking (HCD);

[0093] Precursor ion mass tolerance: ±15ppm;

[0094] fragment tolerance:±15ppm;

[0095] Enzymatic specificity: trypsin KR_C; semi-specific;

[0096] variable modification:oxidation(M);

[0097] Filter tolerance: ±10ppm;

[0098] The false discovery rate (FDR): 100%.

[0099] (2) The false discovery rate (FDR) in the pLink2 software shown in step (1) was adjusted to 5%, and identification was performed according to the method shown in step (1) to obtain the platinum cross-linked peptide 2 output by the pLink2 software.

[0100] 2. Experimental Results

[0101] The identification results of platinum cross-linked peptides are shown in Table 1.

[0102] Table 1 Identification results of platinum cross-linked peptides

[0103] Identification methods Identification results (number of platinum cross-linked peptides) Step 1 75 Step 2(1) 574 Step 2(2) 6

[0104] The results showed that when the pLink2 software was used according to the prior art and FDR was set to 5% to identify platinum cross-linked peptides, i.e., the method shown in step 2(2), only 6 platinum cross-linked peptides could be identified for the data after cross-linking of protein GPb(P00489) and platinum cross-linker Transplatin. When the FDR of the pLink2 software was set to 100%, 574 platinum cross-linked peptides were identified. Although the number of identified platinum cross-linked peptides increased significantly, the accuracy could not be guaranteed, and many false positive identifications occurred.

[0105] Using the method shown in step 1 of the present invention, 75 platinum cross-linked peptides can be identified for the data after cross-linking of protein GPb (P00489) and platinum cross-linker Transplatin, and the accuracy of the identified 75 platinum cross-linked peptides is 100%; the specific information of the 75 platinum cross-linked peptides is shown in Table 2.

[0106] Table 2 75 platinum cross-linked peptides identified by the method shown in step 1

[0107]

[0108]

[0109]

[0110] The platinum cross-linked peptide information shown in Table 2 is expressed in the form of "α peptide + cross-linker + β peptide", where "-" represents the cross-linked peptide platinum cross-linker Transplatin, and (X) represents that the cross-linking site of the platinum cross-linker is located at the X position on the peptide.

[0111] Example 2 Identification of cross-linking sites of platinum cross-linked peptide segment 1

[0112] 1. Experimental Methods

[0113] The cross-linking site of the platinum cross-linked peptide 1 identified in Example 1 (the platinum cross-linked peptide shown in No. 68 in Table 2 of Example 1) was identified, wherein the amino acid sequence of the α peptide of the platinum cross-linked peptide 1 is shown in SEQ ID NO: 1, and the amino acid sequence of the β peptide of the platinum cross-linked peptide 1 is shown in SEQ ID NO: 2, and the α peptide and the β peptide are connected by a platinum cross-linking agent Transplatin (transplatin); the steps for identifying the cross-linking site of the platinum cross-linked peptide 1 are as follows:

[0114] 1. Perform mass spectrometry detection on the platinum cross-linked peptide segment 1, and obtain a secondary mass spectrometry spectrum of the platinum cross-linked peptide segment 1;

[0115] 2. Treat the platinum cross-linked peptide 1 according to the method shown in step 2 of Example 1 to obtain fragment ions y and b of the platinum cross-linked peptide 1, as well as fragment ions Y and B that cannot be fragmented by mass spectrometry;

[0116] The positions of y ions, b ions, Y ions and B ions of the platinum cross-linked peptide segment 1 are marked on the secondary mass spectrum of the platinum cross-linked peptide segment 1 to obtain the secondary mass spectrum of the platinum cross-linked peptide segment 1. Figure 1 ;

[0117] 3. Treating the α peptide segment and the β peptide segment of the platinum cross-linked peptide segment 1 according to the method shown in step 3 of Example 1 to obtain the mass spectrometry fragment ions Y' ions and B' ions of the α peptide segment and the β peptide segment of the platinum cross-linked peptide segment 1, and the fragment ion 1 of the side chain cleavage of the platinum cross-linking agent Transplatin;

[0118] Secondary mass spectrometry of platinum cross-linked peptide 1 Figure 1 The positions of Y' ion, B' ion and fragment ion 1 of platinum cross-linked peptide 1 are marked on the top to obtain the secondary mass spectrum of platinum cross-linked peptide 1. Figure 2 ;

[0119] 4. Treating the α peptide segment and the β peptide segment of the platinum cross-linked peptide segment 1 according to the method shown in step 4 of Example 1 to obtain fragment ions Y" and B" ions in which both the α peptide segment and the β peptide segment of the platinum cross-linked peptide segment 1 are broken, and fragment ion 2 in which the side chain of the platinum cross-linking agent Transplatin is broken;

[0120] And in the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 2 The positions of the Y” ion, B” ion and fragment ion 2 of the platinum cross-linked peptide segment 1 are marked on the top to obtain the secondary mass spectrum of the platinum cross-linked peptide segment 1. Figure 3 ;

[0121] 5. Secondary mass spectrometry based on platinum cross-linked peptide 1 Figure 3 , determine the cross-linking site of platinum cross-linked peptide 1.

[0122] 2. Experimental Results

[0123] The secondary mass spectrometry spectrum of platinum cross-linked peptide 1 is as follows Figure 2 As shown; A is the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 1 , B is the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 2 , C is the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 3 .

[0124] The amino acid sites at which the platinum cross-linker Transplatin (rebuttal) can undergo cross-linking reactions include M, H, C, D, E, R, K, S, T, and Y; therefore, the possible cross-linking sites of the platinum cross-linker Transplatin (rebuttal) on the platinum cross-linked peptide segment 1 include: K, R, H, H, T, K on the α peptide segment, and T, T, R on the β peptide segment.

[0125] The results showed that the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 1 ( Figure 2 A) shows the secondary mass spectrometry of the b1 ion, b5 ion, y1 ion and y2 ion on the α peptide segment of the platinum cross-linked peptide segment 1. Figure 1 The mass of the platinum cross-linking agent Transplatin is not shown in the figure (the m / z corresponding to the b ion is equal to the mass-to-charge ratio of the b ion), while the Y8 ion on the α peptide segment is not shown in the secondary mass spectrum of the platinum cross-linking peptide segment 1. Figure 1 The mass of the platinum crosslinker Transplatin is shown in the figure (the m / z corresponding to the Y ion is equal to the sum of the mass-to-charge ratio of the y ion corresponding to the α peptide plus the mass-to-charge ratio of the platinum crosslinker plus the mass-to-charge ratio of the β peptide), indicating that the crosslinking site of the α peptide in the platinum crosslinked peptide 1 is located on the right side of the Y8 ion and on the left side of the y2 ion (i.e., it may be located on the H (6) , H (8) or T (10) (above); The y1 ion on the β-peptide of the platinum cross-linked peptide 1 is in the secondary mass spectrometry of the platinum cross-linked peptide 1 Figure 1 The mass of the platinum cross-linking agent Transplatin is not shown in the secondary mass spectrum of the platinum cross-linking peptide 1, while the B2 ion on the β peptide segment shows the mass of the platinum cross-linking agent Transplatin (the m / z corresponding to the B ion is equal to the sum of the mass-to-charge ratio of the b ion corresponding to the β peptide segment plus the mass-to-charge ratio of the platinum cross-linking agent plus the mass-to-charge ratio of the α peptide segment), indicating that the cross-linking site of the β peptide segment in the platinum cross-linking peptide 1 is located on the left side of the B2 ion (i.e., on the left side of the T (1) superior).

[0126] Secondary mass spectrometry of platinum cross-linked peptide 1 Figure 2 ( Figure 2 B) shows the Y'9 ion, 1(Y'9) ion and B' on the α-peptide of the platinum cross-linked peptide 1. 12 Secondary mass spectrometry of ions in platinum cross-linked peptide 1 Figure 2 The mass of the platinum cross-linking agent Transplatin is shown in the figure, and the secondary mass spectrometry of the platinum cross-linked peptide segment 1 is shown in the figure. Figure 1, indicating that the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 1 is located at MII, while the platinum cross-linker Transplatin does not cross-link with I, that is, the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 1 is located at H (6) , H (8) , T (10) where 1(Y'9) ion indicates that the side chain of the platinum crosslinker Transplatin on the Y'9 ion is broken and fragment ion 1 is detected in step 3.

[0127] Secondary mass spectrometry of platinum cross-linked peptide 1 Figure 3 ( Figure 2 C) shows that the Y”9 ion, 2(B6) ion, 2(B9) ion and 2(B 11 ) ions in the secondary mass spectrometry of platinum cross-linked peptide 1 Figure 2 The mass of the platinum cross-linker Transplatin is shown in the figure, and the secondary mass spectrometry of the platinum cross-linked peptide 1 is shown in the figure. Figure 1 , indicating that the cross-linking site of the α-peptide in the platinum cross-linked peptide 1 is located at H (6) 2(B6) ions, 2(B9) ions and 2(B 11 ) ions represent B6 ions, B9 ions and B 11 The platinum crosslinker Transplatin side chain on the ion is broken and detected as fragment ion 2 in step 4.

[0128] In summary, the cross-linking site of the α-peptide in the platinum cross-linked peptide 1 is located at H (6) The cross-linking site of the β peptide in the platinum cross-linked peptide 1 is located at T (1) The use of this identification method successfully and precisely located the platinum cross-linking site of platinum cross-linked peptide 1.

[0129] Example 3 Identification of the cross-linking site of platinum cross-linked peptide segment 2

[0130] 1. Experimental Methods

[0131] The cross-linking site of the platinum cross-linked peptide segment 2 identified in Example 1 (the platinum cross-linked peptide segment shown in No. 54 in Table 2 of Example 1) was identified, wherein the amino acid sequence of the α peptide segment of the platinum cross-linked peptide segment 2 is shown in SEQ ID NO: 3, and the amino acid sequence of the β peptide segment of the platinum cross-linked peptide segment 2 is shown in SEQ ID NO: 4, and the α peptide segment and the β peptide segment are connected by a platinum cross-linking agent Transplatin (reverse platinum); the identification steps of the cross-linking site of the platinum cross-linked peptide segment 2 are as shown in the experimental method of Example 2, and the secondary mass spectrometry spectrum of the platinum cross-linked peptide segment 2 is obtained. Figure 1 , two Mass spectrometry Figure 2 and two Mass spectrometry Figure 3 , and determined the cross-linking site of platinum cross-linked peptide 2.

[0132] 2. Experimental Results

[0133] The secondary mass spectrometry spectrum of platinum cross-linked peptide 2 is as follows Figure 3 As shown, A is the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 1 , B is the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 2 , C is the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 3 .

[0134] The results showed that the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 1 ( Figure 3 A) shows the secondary mass spectrometry of the b2 ion, y6 ion, y3 ion and y1 ion on the α peptide segment of the platinum cross-linked peptide segment 2. Figure 1 The mass of the platinum cross-linking agent Transplatin is not shown, indicating that the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 2 is located in the middle area between the b2 ion and the y6 ion (that is, it may be located in the Y (3) or D (6) ); The y1 ion on the β-peptide of the platinum cross-linked peptide segment 2 is in the secondary mass spectrometry of the platinum cross-linked peptide segment 2 Figure 1 The mass of the platinum cross-linker Transplatin is shown in the figure. The mass of the Y3 ion in the secondary mass spectrum of the platinum cross-linked peptide segment 2 is shown in the figure. Figure 1 The mass of the platinum cross-linking agent Transplatin is shown in the figure, indicating that the cross-linking site of the β peptide in the platinum cross-linked peptide segment 2 is located in the middle area between the Y3 ion and the y1 ion (i.e., located in the D (13) ).

[0135] Secondary mass spectrometry of platinum cross-linked peptide 2 Figure 2 ( Figure 3 B) shows that 1 (B') on the α-peptide of platinum cross-linked peptide 2 13 ) ions in the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 2 The mass of the platinum cross-linking agent Transplatin is shown in the figure, and the secondary mass spectrometry of the platinum cross-linked peptide segment 2 is shown in the figure. Figure 1 The cross-linking site of the α peptide in the platinum cross-linked peptide 2 is located in the middle region between the b2 ion and the y6 ion (that is, it may be located in the Y (3) or D (6) ).

[0136] Secondary mass spectrometry of platinum cross-linked peptide 2 Figure 2 ( Figure 3 C) shows that Y" on the α peptide segment of platinum cross-linked peptide segment 1 13ions, 2(Y” 12 ) ions and B”9 ions in the secondary mass spectrometry of platinum cross-linked peptide 2 Figure 3 The mass of the platinum cross-linking agent Transplatin is shown in the figure, indicating that the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 2 is located at 2(Y" 12 ) ion and B"9 ion, that is, between D (6) Place.

[0137] In summary, the cross-linking site of the α-peptide in the platinum cross-linked peptide 2 is located at D (6) The cross-linking site of the β peptide in the platinum cross-linked peptide 2 is located at D (13) The use of this identification method successfully and precisely located the platinum cross-linking site of platinum cross-linked peptide 2.

[0138] Example 4 Identification of the cross-linking site of platinum cross-linked peptide segment 3

[0139] 1. Experimental Methods

[0140] The cross-linking site of the platinum cross-linked peptide segment 3 identified in Example 1 (the platinum cross-linked peptide segment shown in No. 12 in Table 2 of Example 1) was identified, wherein the amino acid sequence of the α peptide segment of the platinum cross-linked peptide segment 3 is shown in SEQ ID NO: 5, and the amino acid sequence of the β peptide segment of the platinum cross-linked peptide segment 3 is shown in SEQ ID NO: 6, and the α peptide segment and the β peptide segment are connected by a platinum cross-linking agent Transplatin (reverse platinum); the identification step of the cross-linking site of the platinum cross-linked peptide segment 3 is as shown in the experimental method of Example 2, and the secondary mass spectrometry spectrum of the platinum cross-linked peptide segment 3 is obtained. Figure 1 , two Mass spectrometry Figure 2 and two Mass spectrometry Figure 3 , and determined the cross-linking site of platinum cross-linked peptide 3.

[0141] 2. Experimental Results

[0142] The secondary mass spectrometry spectrum of platinum cross-linked peptide 3 is as follows Figure 4 As shown, A is the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 1 , B is the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 2 , C is the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 3 .

[0143] The results showed that the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 1 ( Figure 4 A) shows the secondary mass spectrometry of the y1 ion on the α-peptide of the platinum-cross-linked peptide 3. Figure 1 The mass of the product without the platinum crosslinker Transplatin is shown in10 Ion and B 11 Secondary mass spectrometry of ions in platinum cross-linked peptide 3 Figure 1 The mass of the platinum cross-linking agent Transplatin is shown in the figure, indicating that the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 3 is located at Y 10 Ion and B 11 The middle region of the ion (i.e., located at Y (7) , S (9) or E (11) The b2 ion and y1 ion on the β-peptide of the platinum cross-linked peptide segment 3 are in the secondary mass spectrometry of the platinum cross-linked peptide segment 3. Figure 1 The mass of the platinum cross-linker Transplatin is shown in the figure. The mass of the Y6 ion in the secondary mass spectrum of the platinum cross-linked peptide segment 3 is shown in the figure. Figure 1 The mass of the platinum cross-linking agent Transplatin is shown in the figure, indicating that the cross-linking site of the β peptide in the platinum cross-linked peptide segment 3 is located in the middle region between the Y6 ion and the y1 ion (i.e., located in the T (5) or R (7) place).

[0144] Secondary mass spectrometry of platinum cross-linked peptide 3 Figure 2 ( Figure 4 B) shows that the Y' on the α peptide of the platinum cross-linked peptide 3 14 ions, 1(Y' 14 ) ions, B 11 ions and 1(B" 11 ) ions in the secondary mass spectrometry of platinum cross-linked peptide 3 Figure 2 The mass of the platinum cross-linking agent Transplatin is shown in the figure, and the secondary mass spectrometry of the platinum cross-linked peptide segment 3 is shown in the figure. Figure 1 The cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 3 is located at Y 10 Ion and B 11 The middle region of the ion (i.e., located at Y (7) , S (9) or E (11) place).

[0145] Secondary mass spectrometry of platinum cross-linked peptide 3 Figure 3 ( Figure 4 C) shows that Y" on the α-peptide of platinum cross-linked peptide 3 15 ions, B”7 ions and B” 13 Secondary mass spectrometry of ions in platinum cross-linked peptide 3 Figure 3 The mass of the platinum cross-linking agent Transplatin is shown in the figure, and the secondary mass spectrometry of the platinum cross-linked peptide segment 3 is shown in the figure. Figure 1 and two Mass spectrometry Figure 2, indicating that the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 3 is located at Y 10 ion and B"7 ion, that is, between Y (7) Secondary mass spectrometry of 2(Y6), Y”4 and B”5 ions on the β-peptide of platinum cross-linked peptide 3 Figure 3 The mass of the platinum cross-linking agent Transplatin is shown in the figure, indicating that the cross-linking site of the β peptide segment in the platinum cross-linked peptide segment 3 is located between the Y4 ion and the B5 ion, that is, at T (5) Place.

[0146] In summary, the cross-linking site of the α peptide segment in the platinum cross-linked peptide segment 3 is located at Y (7) The cross-linking site of the β peptide in the platinum cross-linked peptide segment 3 is located at T (5) The use of this identification method successfully and precisely located the platinum cross-linking site of platinum cross-linked peptide 3.

[0147] Comparative Example 1: A method for identifying platinum cross-linked peptides

[0148] 1. Experimental Methods

[0149] The protein GPb (P00489) and the platinum crosslinker Transplatin (transplatin, expressed as Pt1N2H4) were mixed at a molar ratio of 1:50, and the crosslinking reaction was carried out at 37°C for 60 minutes. Then, the quencher Histidine was added at a molar ratio of 1:50 to the platinum crosslinker and the quencher for 30 minutes to obtain a platinum crosslinked protein;

[0150] The platinum cross-linked protein was mixed with 16M urea at a volume ratio of 1:1 and denatured for 10 minutes. The denatured platinum cross-linked protein was then diluted with an aqueous ammonium bicarbonate solution until the denatured platinum cross-linked protein contained 1.6M urea, thereby obtaining a diluted platinum cross-linked protein solution.

[0151] 0.1 μg of trypsin was added to 2 μg of diluted platinum cross-linked protein solution and digested for 12 hours, then desalted using a C18 column and diluted to 0.1 μg / μL of protein in the platinum cross-linked protein solution to obtain candidate platinum cross-linked peptides, which were then detected by mass spectrometry to obtain spectral data for each candidate platinum cross-linked peptide.

[0152] The spectrum data of each candidate platinum cross-linked peptide segment was input into the pLink2 software for identification, and the α peptide segment and β peptide segment of each candidate platinum cross-linked peptide segment were obtained, and the fragment ions y ions and b ions of each candidate platinum cross-linked peptide segment, as well as the fragment ions Y ions and B ions of the platinum cross-linked peptide segment that could not be broken by mass spectrometry were matched;

[0153] The parameters of the pLink2 software are set as follows: Crosslinker: Pt1N2H4, Pt1N1H1, Pt1H -2 ;

[0154] flow type: conventional crosslinking (HCD);

[0155] Precursor ion mass tolerance: ±15ppm;

[0156] fragment tolerance:±15ppm;

[0157] Enzymatic specificity: trypsin KR_C; semi-specific;

[0158] variable modification:oxidation(M);

[0159] Filter tolerance: ±10ppm;

[0160] The false discovery rate (FDR): 100%.

[0161] The α peptide and β peptide of each candidate platinum cross-linked peptide were input into MS2-autoassign-Pt respectively, and the selected platinum cross-linked peptides were obtained after removing the false positive data by isotope matching, and the mass spectrometry fragment ions Y' and B' of the α peptide and β peptide of each selected platinum cross-linked peptide were identified;

[0162] The false positive data are: candidate platinum cross-linked peptides with less than 2 fragment ions containing 3 platinum isotope peaks in the isotope matching results;

[0163] MS2-autoassign-Pt is derived from the Github database (github.com / HARUDAY404 / MS2-autoassign-Pt). The parameters of MS2-autoassign-Pt are set as follows: formula of labeling: Pt1N2H4, Pt1N1H1, Pt1H -2 ;Tolerance in ppm: 50; Intensity cutoff%: 5%.

[0164] The obtained y ions, b ions, Y ions, B ions, Y' ions, and B' ions are combined to obtain a fragment ion library 1 of each screened platinum cross-linked peptide segment.

[0165] The peptides that do not meet the conditions are removed from the screened platinum cross-linked peptides to obtain platinum cross-linked peptide 3;

[0166] The condition is that the screened platinum cross-linked peptide contains at least 4 fragment ions in the fragment ion library of each screened platinum cross-linked peptide.

[0167] 2. Experimental Methods

[0168] According to the method shown in step 1, for the data after cross-linking of protein GPb (P00489) and platinum cross-linker Transplatin, the obtained platinum cross-linked peptide segment 3 includes 31 platinum cross-linked peptide segments, and the specific information of the 31 platinum cross-linked peptide segments is shown in Table 3.

[0169] Table 3 31 platinum cross-linked peptides

[0170]

[0171]

[0172] Results show that: using the method shown in step 1, compared with the method shown in Example 1, the number of identifications of platinum cross-linked peptides was significantly reduced, and the precise positioning of the cross-linking sites of the coach peptides could not be achieved.

[0173] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. For ordinary technicians in this field, other different forms of changes or modifications can be made based on the above descriptions and ideas. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A method for identifying platinum cross-linked peptides, characterized in that: The following steps are involved: S1. cross-linking the platinum cross-linking agent and the protein and performing enzyme cleavage to obtain candidate platinum cross-linked peptides and performing mass spectrometry detection to obtain spectrum data of each candidate platinum cross-linked peptide; S2. Input the spectrum data of each candidate platinum cross-linked peptide obtained in step S1 into pLink2 software for identification, obtain the α peptide and β peptide of each candidate platinum cross-linked peptide, and match the fragment ions y and b of each candidate platinum cross-linked peptide, as well as the fragment ions Y and B of the platinum cross-linked peptide that cannot be broken by mass spectrum; S3. The α peptide segment and β peptide segment of each candidate platinum cross-linked peptide segment obtained in step S2 are respectively input into MS2-autoassign-Pt, and each screened platinum cross-linked peptide segment is obtained after removing false positive data by isotope matching, and the mass spectrometry fragment ions Y' ions and B' ions of the α peptide segment and β peptide segment of each screened platinum cross-linked peptide segment, as well as the fragment ion 1 of the side chain breakage of the platinum cross-linker shown in step S1 are identified; The false positive data are: candidate platinum cross-linked peptides with less than 2 fragment ions containing 3 platinum isotope peaks in the isotope matching results; S4. The α peptide segment and the β peptide segment of each screened platinum cross-linked peptide segment obtained in step S3 are simultaneously input into MS2-autoassign-Pt for identification, and the fragment ions Y" and B" ions of the α peptide segment and the β peptide segment of each screened cross-linked peptide segment are obtained, as well as the fragment ion 2 of the side chain of the platinum cross-linking agent shown in step S1; S5. Combine the y ion, b ion, Y ion, B ion obtained in step S2, the Y' ion, B' ion, fragment ion 1 obtained in step S3, the Y" ion, B" ion and fragment ion 2 obtained in step S4 to obtain a fragment ion library of each screened platinum cross-linked peptide segment; S6. removing peptides that do not meet the conditions from the screened platinum cross-linked peptides obtained in step S3 to obtain platinum cross-linked peptides; The condition is: after screening, the platinum cross-linked peptide segment contains at least 4 fragment ions in the fragment ion library obtained in step S5.

2. The identification method according to claim 1, characterized in that: The platinum cross-linking agent in step S1 is a cis-platinum cross-linking agent and / or a trans-platinum cross-linking agent; The chemical formula of the cis-platinum cross-linking agent is shown in Formula I, and the chemical formula of the cis-platinum cross-linking agent is shown in Formula II; Among them, R1 and R2 are inert groups, and X1 and X2 are active groups.

3. The identification method according to claim 2, characterized in that: The platinum cross-linking agent in step S1 is reverse platinum.

4. The identification method according to claim 1, characterized in that: The step S1 of cross-linking the platinum cross-linking agent and the protein is specifically as follows: The protein is cross-linked with a platinum cross-linking agent at 25°C to 37°C, and then the reaction is quenched with a quencher.

5. The identification method according to claim 4, characterized in that: The quencher is histidine.

6. The identification method according to claim 1, characterized in that: The parameters of MS2-autoassign-Pt shown in step S3 are set to the formula of labeling: Pt1N2H4, Pt1N1H1, Pt1H -2 ;Tolerance in ppm: 1~50; intensity cutoff%: 1%~10%.

7. Use of the identification method according to any one of claims 1 to 6 in identifying platinum cross-linked peptides.

8. Use of the identification method according to any one of claims 1 to 6 in locating the cross-linking site of a platinum cross-linked peptide segment.

9. Use of the identification method according to any one of claims 1 to 6 in analyzing protein structure.

10. Use of the identification method according to any one of claims 1 to 6 in guiding the study of drug resistance and / or toxicity of platinum drugs.